newsfilter
← Latest News
Business Wire·

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

Sundance™ Sirolimus Drug-Coated Balloon exhibits excellent safety profile Primary patency maintained at 24 months in 71.4% of per protocol analysis population Surmodics, Inc. (NASDAQ:SRDX), a leading provider